Drug and drug management has just allowed preventable drugs to prevent HIV drugs.
On Wednesday afternoon, FDA was allowed GDA Science Science ‘Lenacavir as a more convenient way of prophylaxis (PrEP). In clinical trials, the medicine was shown to be very successful in preventing HIV infection when considered twice a year. At the same time, lawyers appeal to Gilead and US officials to ensure that the medicine is widely achieved by the community.
“PrEP is one of the most important tools by completing the HIV epidemic. “But this wonderful tree will only work as well as it is available and inexpensive.”
FDA was first approved by Lenacapavir in 2022 as treated antiretroviral HIV, sold under the Sunlumna name. It was the beginning of the Administrative Management of HIV Phase for HIV aimed at the CAPSID, or the shell, the virus. That alone makes Lenacavavir so important, as it can treat diseases that can cause other drugs. However, the greatest drug strength can come from acquaintance like vaccines – as the ability to prevent the virus that can find it in the first place.
Last year, Gilead issued the results of its purposeful purpose 1 The III test, which tested a double PrECAPAVIvir injection for women. Drugs that run out of Prepeeleded Fection at 100% prevention rate. The future test and demonstrated a measurement measurement of 99.9% between the CISGent men, male and female transgerns, as well as non-sex. The success of the tree was so impressed that the science journal named him looked at the year research. Gilead is now studying now if a single dose of the year can work effectively.
Like a monumental as Lenacapavir’s arrival may, their expenses may set a problem – given to Gilead reputation. The company is a long-term company and usually increases the prices of its former Pikhard’s priceminous investigations. In 2023, the company resolved the process of the action of the allegations.
The NBC news reported on Wednesday that the Lenacapavir version, sold under the name of the demo product, will have a $ 14,109 list of each injection, or $ 2,352 per month. In the announcement of FDA approval, Gilead said that “working closely with the human care programs and other payments to ensure comprehensive insurance.” It will also establish programs aimed at reducing the cost of ZTUGU other than the low package such as $ 0 for other qualifications of insurance or without insurance.
The time will have to tell if these guarantees will be enough to make this drug cost more and accessible to Americans and ultimately everyone on earth.
“SFILAMENCE Calls of Gilead and US Government is doing their best to make sure that many people who want Lenacapavir can find it,” said Frost.
